An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
- Conditions
- Chronic Hepatitis C
- Interventions
- Registration Number
- NCT01513941
- Lead Sponsor
- Janssen-Cilag International NV
- Brief Summary
The purpose of this study is to evaluate the effectiveness and safety of telaprevir, given with pegylated-interferon-alfa-2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in the treatment of hepatitis C in patients infected with both chronic hepatitis C virus (HCV-1) and human immunodeficiency virus (HIV-1).
- Detailed Description
This is an open-label (both participant and investigator know the name of the medication given at a certain moment), single-arm, multicenter study in HCV treatment-naive and treatment-experienced patients infected with both chronic HCV-1 and HIV-1 to determine the efficacy and safety of telaprevir given with Peg-IFN-alfa-2a and RBV. The study will consist of 3 phases: a screening phase, an open-label treatment phase up to 48 weeks, and a follow-up period of 24 weeks. All patients will receive 12 weeks of treatment with telaprevir given with Peg-IFN-alfa-2a and RBV. At week 12 telaprevir dosing will end and patients will continue on Peg-IFN-alfa-2a and RBV. The total treatment duration in this study will be 24 or 48 weeks depending on the patient's prior HCV treatment status, liver disease status, and individual on-treatment virologic response in this study (equal response guided therapy). The maximum total duration of participation in the study for an individual participant will be approximately 76 weeks (screening included). Approximately 150 patients infected with both chronic HCV-1 and HIV-1 are planned to be enrolled.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 163
- Chronic (detectable HCV Ribonucleic acid (RNA) more than 6 months prior screening or histological diagnosis based on liver biopsy or fibroscan) HCV infection genotype 1 with HCV RNA level greater than 1,000 IU/mL
- Confirmed diagnosis of HIV-1 infection greater than 6 months before the screening visit
- CD4 count greater than 300 cells/mm3 at screening and no value less than 200 cells/mm3 within 6 months of screening visit
- HIV-1 RNA undetectable by an ultrasensitive assay at least once within 90 days of the screening visit
- No HIV RNA values greater than 200 copies/mL within 6 months of the screening visit
- Currently taking one of the permitted anti-HIV regimens for greater than or equal to12 weeks
- Anticipated need to switch anti-HIV regimen from screening through the Telaprevir treatment period
- Infection or co-infection with HCV other than genotype 1
- Contraindication to the administration of Peg-IFN-alfa or RBV
- Hepatitis B virus (HBV) co-infection
- Acute or active condition of HIV-associated opportunistic infection within 6 months of screening
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Telaprevir plus Pegylated-Interferon-alfa-2a /ribavirin (RBV) Pegylated-Interferon-alfa-2a All patients who will receive 12 weeks of treatment with telaprevir 750 mg q8h except for patients on efavirenz will receive 1125 mg every 8 hours (q8h) in combination with Pegylated-Interferon-alfa-2a (Peg-IFN-alfa-2a) 180 μg/week and RBV 800 mg/day. At Week 12, telaprevir dosing will end and the patients will continue on Peg-IFN-alfa-2a and RBV. Telaprevir plus Pegylated-Interferon-alfa-2a /ribavirin (RBV) Ribavirin All patients who will receive 12 weeks of treatment with telaprevir 750 mg q8h except for patients on efavirenz will receive 1125 mg every 8 hours (q8h) in combination with Pegylated-Interferon-alfa-2a (Peg-IFN-alfa-2a) 180 μg/week and RBV 800 mg/day. At Week 12, telaprevir dosing will end and the patients will continue on Peg-IFN-alfa-2a and RBV. Telaprevir plus Pegylated-Interferon-alfa-2a /ribavirin (RBV) Telaprevir All patients who will receive 12 weeks of treatment with telaprevir 750 mg q8h except for patients on efavirenz will receive 1125 mg every 8 hours (q8h) in combination with Pegylated-Interferon-alfa-2a (Peg-IFN-alfa-2a) 180 μg/week and RBV 800 mg/day. At Week 12, telaprevir dosing will end and the patients will continue on Peg-IFN-alfa-2a and RBV.
- Primary Outcome Measures
Name Time Method Proportion of patients achieving undetectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels Up to 48 weeks Proportion of patients achieving sustained virologic response (SVR) undetectable plasma HCV RNA levels 12 weeks after the last planned dose of study medication.
- Secondary Outcome Measures
Name Time Method Change from baseline in log HCV RNA values Baseline and week 48 Change from baseline in log HCV RNA values at each time point during treatment.
Proportion of patients achieving undetectable HCV RNA levels at Week 4 Up to 48 weeks The proportion of patients who achieve rapid virologic response (RVR) and undetectable HCV RNA levels at Week 4 of treatment.
Proportion of patients achieving undetectable HCV RNA levels at Week 4 and Week 12 (eRVR) Up to 48 weeks Proportion of patients achieving undetectable HCV RNA levels at Week 4 and Week 12 of treatment (eRVR).
Proportion of patients with relapse achieving detectable HCV RNA levels after previously undetectable HCV RNA levels Up to 48 weeks Proportion of patients who relapse (having confirmed detectable HCV RNA during the follow-up period after previous undetectable HCV RNA levels (less than 25 IU/mL, undetectable) at planned end of treatment.
Proportiond of patients achieving undetectable HCV RNA levels Up to 48 weeks Proportion of patients achieving SVR24 planned, defined as having undetectable plasma HCV RNA levels 24 weeks after the last planned dose of study medication.
Proportion of patients achieving undetectable HCV RNA levels at Week 12 Up to 48 weeks Proportion of patients achieving undetectable HCV RNA levels at Week 12 of treatment.
Proportion of patients achieving undetectable HCV RNA at the actual end of treatment Up to 48 weeks Proportion of patients having undetectable HCV RNA levels at the actual end of treatment (ie, Week 24, Week 48, or early discontinuation).
Proportion of patients achieving less than 25 IU/mL Up to 48 weeks Proportion of patients having less than 25 IU/mL at the planned end of treatment (ie, Week 24 or Week 48).
Proportion of patients with on-treatment virologic failure Up to 48 weeks Proportion of patients with on-treatment virologic failure (an increase greater than 1 log in HCV RNA level from the lowest level reached, or a value of HCV RNA greater than 100 IU/mL in patients whose HCV RNA has previously become less than 25 IU/mL during treatment).
Proportion of patients with relapse achieving detectable HCV RNA levels after previous HCV RNA levels Up to 48 weeks Proportion of patients who relapse, defined as having confirmed detectable HCV RNA during the follow-up period after previous HCV RNA less than 25 IU/mL at planned end of treatment.